Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk for a much-awaited entry into the world's most populous country grappling with increasing rates of obesity and diabetes.

Mounjaro (tirzepatide) is an FDA-approved antidiabetic injection gaining popularity for its effectiveness in weight management and diabetes treatment. Offering a dual-action mechanism targeting GLP-1 and GIP receptors,

The global weight-loss drug market is expected to reach $150 billion in the next decade. By 2026, semaglutide (the active ingredient in Wegovy and Ozempic) will go off-patent in India, allowing local firms to introduce cheaper alternatives.